BofA raised the firm’s price target on Insmed (INSM) to $214 from $212 and keeps a Buy rating on the shares. After having conducted an updated prescriber survey to gauge launch progress, the firm is raising its Q1 sales forecast to $212M and its FY26 outlook to $1.32B, versus the Visible Alpha consensus at $200M and $1.24B, respectively.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Why Is Invesco QQQ Trust ETF (QQQ) Rising Today, 5/1/2026?
- Why Is Invesco QQQ Trust ETF (QQQ) Trending Higher Today, 4/30/2026?
- Why Is Invesco QQQ Trust ETF (QQQ) Rising Today, 4/29/2026?
- Why Is Invesco QQQ Trust ETF (QQQ) Falling Today, 4/28/2026?
- Invesco QQQ Trust ETF (QQQ) Daily Update, 4/27/2026